265 related articles for article (PubMed ID: 33970190)
1. DNMT3A haploinsufficiency causes dichotomous DNA methylation defects at enhancers in mature human immune cells.
Lim JY; Duttke SH; Baker TS; Lee J; Gambino KJ; Venturini NJ; Ho JSY; Zheng S; Fstkchyan YS; Pillai V; Fajgenbaum DC; Marazzi I; Benner C; Byun M
J Exp Med; 2021 Jul; 218(7):. PubMed ID: 33970190
[TBL] [Abstract][Full Text] [Related]
2. Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies.
Cole CB; Russler-Germain DA; Ketkar S; Verdoni AM; Smith AM; Bangert CV; Helton NM; Guo M; Klco JM; O'Laughlin S; Fronick C; Fulton R; Chang GS; Petti AA; Miller CA; Ley TJ
J Clin Invest; 2017 Oct; 127(10):3657-3674. PubMed ID: 28872462
[TBL] [Abstract][Full Text] [Related]
3. Gain-of-function DNMT3A mutations cause microcephalic dwarfism and hypermethylation of Polycomb-regulated regions.
Heyn P; Logan CV; Fluteau A; Challis RC; Auchynnikava T; Martin CA; Marsh JA; Taglini F; Kilanowski F; Parry DA; Cormier-Daire V; Fong CT; Gibson K; Hwa V; Ibáñez L; Robertson SP; Sebastiani G; Rappsilber J; Allshire RC; Reijns MAM; Dauber A; Sproul D; Jackson AP
Nat Genet; 2019 Jan; 51(1):96-105. PubMed ID: 30478443
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation.
Cypris O; Franzen J; Frobel J; Glück P; Kuo CC; Schmitz S; Nüchtern S; Zenke M; Wagner W
BMC Biol; 2022 Jun; 20(1):141. PubMed ID: 35705990
[TBL] [Abstract][Full Text] [Related]
5. Remethylation of
Ketkar S; Verdoni AM; Smith AM; Bangert CV; Leight ER; Chen DY; Brune MK; Helton NM; Hoock M; George DR; Fronick C; Fulton RS; Ramakrishnan SM; Chang GS; Petti AA; Spencer DH; Miller CA; Ley TJ
Proc Natl Acad Sci U S A; 2020 Feb; 117(6):3123-3134. PubMed ID: 31996479
[TBL] [Abstract][Full Text] [Related]
6. Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans.
Kaasinen E; Kuismin O; Rajamäki K; Ristolainen H; Aavikko M; Kondelin J; Saarinen S; Berta DG; Katainen R; Hirvonen EAM; Karhu A; Taira A; Tanskanen T; Alkodsi A; Taipale M; Morgunova E; Franssila K; Lehtonen R; Mäkinen M; Aittomäki K; Palotie A; Kurki MI; Pietiläinen O; Hilpert M; Saarentaus E; Niinimäki J; Junttila J; Kaikkonen K; Vahteristo P; Skoda RC; Seppänen MRJ; Eklund KK; Taipale J; Kilpivaara O; Aaltonen LA
Nat Commun; 2019 Mar; 10(1):1252. PubMed ID: 30890702
[TBL] [Abstract][Full Text] [Related]
7. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.
Meyer SE; Qin T; Muench DE; Masuda K; Venkatasubramanian M; Orr E; Suarez L; Gore SD; Delwel R; Paietta E; Tallman MS; Fernandez H; Melnick A; Le Beau MM; Kogan S; Salomonis N; Figueroa ME; Grimes HL
Cancer Discov; 2016 May; 6(5):501-15. PubMed ID: 27016502
[TBL] [Abstract][Full Text] [Related]
8. [Functional role of DNMT3A mutation in acute myeloid leukemia].
Koya J; Kurokawa M
Rinsho Ketsueki; 2018; 59(5):602-610. PubMed ID: 29877252
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.
Glass JL; Hassane D; Wouters BJ; Kunimoto H; Avellino R; Garrett-Bakelman FE; Guryanova OA; Bowman R; Redlich S; Intlekofer AM; Meydan C; Qin T; Fall M; Alonso A; Guzman ML; Valk PJM; Thompson CB; Levine R; Elemento O; Delwel R; Melnick A; Figueroa ME
Cancer Discov; 2017 Aug; 7(8):868-883. PubMed ID: 28408400
[TBL] [Abstract][Full Text] [Related]
10. Alterations to
Venugopal K; Feng Y; Shabashvili D; Guryanova OA
Cancer Res; 2021 Jan; 81(2):254-263. PubMed ID: 33087320
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners.
Sandoval JE; Huang YH; Muise A; Goodell MA; Reich NO
J Biol Chem; 2019 Mar; 294(13):4898-4910. PubMed ID: 30705090
[TBL] [Abstract][Full Text] [Related]
12. B1a and B2 cells are characterized by distinct CpG modification states at DNMT3A-maintained enhancers.
Mahajan VS; Mattoo H; Sun N; Viswanadham V; Yuen GJ; Allard-Chamard H; Ahmad M; Murphy SJH; Cariappa A; Tuncay Y; Pillai S
Nat Commun; 2021 Apr; 12(1):2208. PubMed ID: 33850140
[TBL] [Abstract][Full Text] [Related]
13. Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases.
Cheng X; Blumenthal RM
Curr Opin Struct Biol; 2022 Aug; 75():102433. PubMed ID: 35914495
[TBL] [Abstract][Full Text] [Related]
14. Dnmt3a deficiency in the skin causes focal, canonical DNA hypomethylation and a cellular proliferation phenotype.
Chen DY; Ferguson IM; Braun KA; Sutton LA; Helton NM; Ramakrishnan SM; Smith AM; Miller CA; Ley TJ
Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33846253
[TBL] [Abstract][Full Text] [Related]
15. In vivo activity of murine de novo methyltransferases, Dnmt3a and Dnmt3b.
Hsieh CL
Mol Cell Biol; 1999 Dec; 19(12):8211-8. PubMed ID: 10567546
[TBL] [Abstract][Full Text] [Related]
16. Tissue-Biased Expansion of DNMT3A-Mutant Clones in a Mosaic Individual Is Associated with Conserved Epigenetic Erosion.
Tovy A; Reyes JM; Gundry MC; Brunetti L; Lee-Six H; Petljak M; Park HJ; Guzman AG; Rosas C; Jeffries AR; Baple E; Mill J; Crosby AH; Sency V; Xin B; Machado HE; Castillo D; Weitzel JN; Li W; Stratton MR; Campbell PJ; Wang H; Sanders MA; Goodell MA
Cell Stem Cell; 2020 Aug; 27(2):326-335.e4. PubMed ID: 32673568
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for impairment of DNA methylation by the DNMT3A R882H mutation.
Anteneh H; Fang J; Song J
Nat Commun; 2020 May; 11(1):2294. PubMed ID: 32385248
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E2 Leads to the Acquisition of DNMT3A-Dependent Tolerogenic Functions in Human Myeloid-Derived Suppressor Cells.
Rodríguez-Ubreva J; Català-Moll F; Obermajer N; Álvarez-Errico D; Ramirez RN; Company C; Vento-Tormo R; Moreno-Bueno G; Edwards RP; Mortazavi A; Kalinski P; Ballestar E
Cell Rep; 2017 Oct; 21(1):154-167. PubMed ID: 28978469
[TBL] [Abstract][Full Text] [Related]
19. The inherent processivity of the human de novo methyltransferase 3A (DNMT3A) is enhanced by DNMT3L.
Holz-Schietinger C; Reich NO
J Biol Chem; 2010 Sep; 285(38):29091-100. PubMed ID: 20630873
[TBL] [Abstract][Full Text] [Related]
20. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
